Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich

02.05.24 18:45 Uhr

Werte in diesem Artikel

DocMorris AG / Key word(s): AGMEGM
Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich

02.05.2024 / 18:45 CET/CEST


Frauenfeld, 2 May 2024

 

Press release

Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich

  • The shareholders approved the annual report and consolidated and statutory financial statements for 2023 and the Board of Directors' proposal for the appropriation of the balance sheet result 2023.
  • Discharge was granted to all members of the Board of Directors and the Executive Board.
  • All members of the Board of Directors and the Nomination and Compensation Committee were confirmed for a further term of office until the next Annual General Meeting.
  • Amendments to the Articles of Association: The amendments to the provisions in line with the new company law and the main proposal to adjust the threshold for placing an item on the agenda were approved. The additions to the article in the Articles of Association on conditional share capital for financing, acquisitions and other purposes were also approved.
  • Buis Bürgi AG as independent proxy and Ernst & Young AG as auditors were re-elected.
  • The Annual General Meeting approved the Sustainability Report 2023.
  • The shareholders also approved the compensation for the Board of Directors and the Executive Board. Mainly based on the recommendations of a proxy advisor who had already criticised the transparency of the compensation system prior to the Annual General Meeting, the 2023 Compensation Report was rejected in a consultative vote. DocMorris will examine this criticism in detail and seek dialogue on this topic with larger shareholders in order to present a Compensation Report next year that is widely accepted.

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1


Agenda

20 August 2024 2024 Half-year results (conference call/webcast)
15 October 2024 Q3/2024 Trading update

 

DocMorris

The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 

 



End of Media Release


Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1894643

 
End of News EQS News Service

1894643  02.05.2024 CET/CEST

Ausgewählte Hebelprodukte auf DocMorris

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DocMorris

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Nachrichten zu DocMorris AG (ex Zur Rose)

Analysen zu DocMorris AG (ex Zur Rose)

DatumRatingAnalyst
05.06.2024DocMorris BuyJefferies & Company Inc.
04.06.2024DocMorris SellUBS AG
27.05.2024DocMorris BuyWarburg Research
22.05.2024DocMorris AddBaader Bank
21.05.2024DocMorris SellUBS AG
DatumRatingAnalyst
05.06.2024DocMorris BuyJefferies & Company Inc.
27.05.2024DocMorris BuyWarburg Research
22.05.2024DocMorris AddBaader Bank
23.04.2024DocMorris BuyDeutsche Bank AG
19.04.2024DocMorris BuyHauck & Aufhäuser Privatbankiers KGaA
DatumRatingAnalyst
08.01.2024DocMorris Equal-weightMorgan Stanley
31.10.2023DocMorris HoldDeutsche Bank AG
21.10.2023DocMorris HoldDeutsche Bank AG
29.09.2023DocMorris HoldDeutsche Bank AG
29.08.2023DocMorris HoldDeutsche Bank AG
DatumRatingAnalyst
04.06.2024DocMorris SellUBS AG
21.05.2024DocMorris SellUBS AG
16.05.2024DocMorris SellUBS AG
16.04.2024DocMorris SellUBS AG
02.04.2024DocMorris SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DocMorris AG (ex Zur Rose) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"